BioAge Labs (BIOA) logo

BioAge Labs (BIOA) stock

Aging medicines , market cap $260M

Pre-market
$5.58
+0.54%

Close $5.55 -1.77%

Quality Score
-6
Poor
In its industry
#224of 270
Checks firing
1of 14
Transition
From 52-week high
-78.6%
under its best in a year

BIOA's Quality Score fell 1 point on Fri, Nov 13, to -6. Its average daily range rose to 8.0%, with a $108M loss over four quarters and no positive free cash flow.

Follow BIOA's trial news. Pro members can get an alert when BioAge Labs files news, and see its trials, share raises, and its CEO's filings.

Get an alert when BIOA files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…and elevated inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026”Trial data · SEC filing · Nov 5
Cash$352M, about 13 quarters (3.5 years) at the last year's spendingOn Sep 30 · the company says “through 2029”

Why is BIOA down?

Down 47% in 3 months while the S&P 500 fell 2%.

  • Its Nov 5 results: collaboration revenue was $0.3M, from $2.1M a year before; net loss widened to $33.5M, from $20.2M. It fell 4% on Nov 6.

Sources: Price history, Nov 13, 2026; Company release, Nov 5, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

1 more reason, free with an account →3 more reasons why BIOA is down, from its filings, with the timeline, for Pro members.

Key facts on BIOA

Key facts on BIOA
Holding it back28.1% more shares than a year ago
Latest filing8-K, Nov 5 Reported its quarterly results
1 more reason behind BIOA's -6, free with an account →5 more reasons behind BIOA's -6, for Pro members.

What's next

Mon Nov 16: UBS Global Biopharma Conference 2026Investor conference · date confirmed.

Expected to report Wed Mar 24, after the close

After its last 4 reports it closed -3.4% on average, higher 2 of 4 times.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$352M, about 13 quarters (3.5 years) at the last year's spendingOn Sep 30 · the company says “through 2029”

BIOA catalysts

Coming up

4 more coming up, with sizes and sources, for Pro members.

What's next for BIOA, and how long its cash lasts

Next step the company has named

Q4 2026“QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026”Trial data · SEC filing · Nov 5

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
BGE-102 · Obesity and Cardiovascular Risk · Phase 2
Its trial
QUELL-CVPhase 2 · Active · 160 people · main data estimated Nov 30, 2026 · NCT07656727

1 more trial, 4 more milestones and 18 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 13 quarters

$352M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “through 2029” (8-K, Nov 5).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Mar 24, 2026)
  • At-the-market share sales program (S-3ASR, filed Mar 24, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

An officer, Shane Barton, sold 62,566 shares on Jun 30, under a planned sale. 6 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Kristen Fortney’s 11 filings and quotes.

Get an alert when BIOA files news on its trialsA free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

How BIOA ranks in Biotech

BIOA is #224 of 270 by Quality Score.

How BIOA ranks in Biotech
RankStockQuality Score
224BioAge Labs (BIOA) logoBIOABioAge Labs-6

More in Biotech

When does BIOA report earnings, and what happens after?

Expected to report Wed Mar 24, after the close (in 128 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What BIOA reported on Nov 5, 2026

The quarter

A loss of $0.73 a share, from $0.56.

“The $1.8 million decrease was primarily due to a $1.7 million cumulative catch-up adjustment recorded in connection with a September 2026 amendment to the Novartis Agreement, which added $0.9 million of research funding and expanded the research activities to be performed, increasing the total estimated effort required to satisfy the performance obligation.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

BIOA's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The $11.7 million increase in research and development expenses was primarily attributable to a $13.2 million increase in direct costs related to BioAge’s BGE-102 program associated with clinical trial costs for the Company’s ongoing QUELL-CV and QUELL-DME trials and drug product manufacturing costs.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value
$260M
today
Sales
$8.6M
up 45.3% on the year
Free cash flow
-$103M
last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on BIOA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+0.9%+2.6%-3.6%
May 8Aug 5Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close-4.2%-3.6%+2.0%
Aug 5, 2026After close-0.7%+2.6%-4.5%
May 8, 2026Before open-1.7%+0.9%+5.0%

BIOA closed higher after 2 of its last 4 reports.

All 4 reports, and BIOA's Quality Score going into each

BIOA sales and profit by year

Profit by year

Sales grew in 2025, to $9M. It lost money in both years.

BIOA has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on BIOA, and all 14 on every stock.Get in free →

BIOA RSI on Nov 13: 41.9, below its 50-day and 200-day averages

Not scored

RSI 41.9, MACD above signal, below both averages. Not scored.

The deep dive on BIOA

7 more findings on BIOA, each with its source, for Pro members.

BIOA share count over time

28% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of BIOA outstanding, as filed
Shares
outstanding
As
of
46MOct 30, 2026
45.9MJul 31, 2026
44.5MMay 1, 2026
44.4MMar 19, 2026
Offerings, shelves, and splits of BIOA, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Mar 24, 2026
Raised $115M in a sale of shares, about 44% of its market valueJan 22, 2026
Registered shares for a later sale (S-3)Oct 2, 2025
Raised $198M in a sale of shares, about 76% of its market valueSep 26, 2024

BIOA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold BIOA?

In ETFs: BIOA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About BioAge Labs

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

62 employeesEmeryville, CAbioagelabs.com

What BioAge Labs says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property.”

From its annual report, SEC filing · Mar 24, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on BIOA and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn BIOA's score around: 8 things
  • 8 more filings explained, a plain line each
  • 5 more things pulling BIOA's score down
See BIOA's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: BIOA's Quality Score is -6 (Poor), #224 of 270 in Biotech.

What does BIOA's Quality Score say?

BIOA scores -6 today, which Breakaway calls Poor. It is #224 of 270 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 47% in 3 months while the S&P 500 fell 2%. Cash lasts about 13 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is BIOA's Quality Score?

BIOA scores -6 today, which Breakaway calls Poor (below zero). That is #224 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BIOA's -6.

When does BIOA report earnings?

Expected to report Wed Mar 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BIOA closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for BioAge Labs: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.